1 SEC 13D/G filing tracked · Last updated Sep 2, 2026
$SMMT - Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positiv…
